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and most of them (76.0%) were active workers. Daily mean
cigarette consumption during working days was 20.7  9.9.
Mean annual expenses for cigarettes reached €961.5  442.3
and the median expense was €876, although signiﬁcant differ-
ences (p < 0.0001) within gender, age groups, educational level,
work situation and geographic area were observed. Men older
than 46–65 years showed the highest expense, regardless of their
income; and unemployed workers spent more than active
workers on tobacco. A mean annual expense for cigarettes higher
than 1500 € was associated with a higher use of smoking cessa-
tion treatments (p = 0.0009). However, less than 0.9% of
smokers wanted to stop smoking due to economic reasons.
CONCLUSIONS: Smokers who want to quit smoking spend
annually a mean of €961.5 (median of €876) on cigarettes,
although there are signiﬁcant differences within socio-
demographic proﬁles. The higher the expenses for cigarettes are,
the higher the expenses for smoking cessation treatments reach.
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OBJECTIVES: Recent regulatory guidelines emphasize the
importance of patient input in the development of patient
reported outcome (PRO) measures that will be used as clinical
trial endpoints to support labelling claims. In asthma prevention
and management, consensus among clinicians is growing regard-
ing models of asthma control. It is uncertain how closely patient
models concur with clinical perspectives of asthma control. The
objective of this research was to develop a conceptual model of
asthma control based on both patient and clinician input and
explore the congruence of patient and clinical perspectives.
METHODS: Fifty-ﬁve patients discussed the concept of asthma
control in 8 focus groups (2 each in France, Germany, UK & US).
Independently two asthma specialists and two general practitio-
ners were interviewed in each country (18 in total) about their
understanding of asthma control, symptoms and treatments.
Data was analyzed using thematic analysis techniques based on
grounded theory, and conceptual models were developed for
patient and clinician perspectives. RESULTS: When asked what
asthma control meant to them, patients talked about symptoms,
sleep disturbance, tiredness, rescue medication use, activity limi-
tations, the experience of asthma attacks and experiencing panic
and fear. Clinicians focussed primarily on presence and severity
of symptoms and medication use, but also mentioned the ability
of the patient to remain active, patients’ hospitalisation, and
satisfaction with and adherence to medication as being indicators
of asthma control. CONCLUSIONS: Our research suggests that
patient and clinician models are complementary, but not com-
pletely consistent. Both emphasize symptom control and rescue
medication use as key indicators. Patients, however, also consider
emotional responses, tiredness and activity limitations as impor-
tant, whereas clinicians more often considered adherence and
health care utilisation. Differences in the models support the
importance of including both patient and clinical perspectives
when developing PRO measures for clinical trials.
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OBJECTIVES: The perceptions of patients and physicians re-
garding the symptoms and impact of allergic rhinitis (AR) were
assessed in a prospective, international, cross-sectional survey
using a convenience sample of consulting patients. We present the
combined survey results from Germany, France, Italy, Spain and
UK. METHODS: Data were recorded by 1482 patients and
matched with records completed by primary care physicians
and specialists. Diagnostic tests to conﬁrm AR had been per-
formed on 1279 (86.3%) patients. Both physicians and patients
recorded the presence, severity and impact of symptoms. Health-
related quality of life (HRQoL) was assessed. RESULTS: A large
proportion of patients had moderate–severe disease (67.2%;
n = 996), persistent disease (42.5%; n = 630) and co-morbidities
such as asthma (31.5%; n = 467). Patients generally rated their
disease as more severe than did their physicians (P < 0.001). At
the time of the consultation, one-third of all patients reported
that their current nasal and ocular symptoms were moderate or
severe in nature. According to the physicians’ assessment, good
control of nasal and ocular symptoms was achieved in 45.4%
(n = 673) and 51.3% (n = 760) of patients, respectively. Overall,
43.3% (n = 641) of those surveyed were using two or more
medicines for their AR. HRQoL was correlated with disease
severity and with the number of days without symptoms in the
previous 4 weeks. AR had a signiﬁcantly greater impact in
patients with more persistent disease than in those with intermit-
tent disease (2.3  1.3 vs. 1.9  1.2; P < 0.001). Nonetheless,
81.8% (n = 601) of patients with intermittent disease reported
some impairment of their daily life as a result of their AR.
CONCLUSIONS: AR remains a signiﬁcant health problem
because of the high burden of symptoms and its impact on
general well being and HRQoL.
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OBJECTIVES: Shortness of breath, chest tightness, wheeze and
cough are hallmark symptoms of asthma. These can signiﬁcantly
impact a patient’s life causing impairment to a patient’s physical,
emotional and social wellbeing. To evaluate a treatment’s efﬁ-
cacy, it is important to assess endpoints that are important to
patients. This study aimed to conﬁrm symptoms and their impact
which are important to asthma patients. METHODS: Fifteen
patients with asthma, meeting predeﬁned inclusion criteria were
recruited by MAPI Values in Boston, USA. All patients con-
sented. The semi-structured interviews explored symptoms and
impact of symptoms. Patients also completed the Asthma
Control TestTM (ACT) and the Asthma Quality of Life Question-
naire (AQLQ(S)). Taped interviews were transcribed maintaining
anonyminity and analysed to answer the key questions in the
interview guide. Findings of the ﬁrst 11 (75%) interviews were
compared with the ﬁnal 4 (25%) interviews to determine the
level of consistency in the pattern of responses. RESULTS: All
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